drugset / Trial / NCT02819999
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to test the effect of rovalpituzumab tesirine in the frontline treatment of small cell lung cancer (SCLC).
Timeline
- Start
- 2016-10
- Primary completion
- 2019-05-31
- Completion
- 2019-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Rovalpituzumab tesirine | Other / unclassified | 0.1 mg/kg | Intravenous |
| Subject | Rovalpituzumab tesirine | Other / unclassified | 0.3 mg/kg | Intravenous |